A city-based medtech firm has secured investment of €6.4m to advance a revolutionary new stroke treatment.
Ceroflo will use the latest funding to advance an innovative stent that works to prevent one of the leading causes of stroke.
That's Intracranial atherosclerotic disease - or IACD.
The €6.4m will now allow Ceroflo to bring the stent to 30 patients in the first human trials.
Advertisement
